FDA Panel Finds Fatal Risks In GE, Covidien MRI Drugs

Law360, New York (December 9, 2009, 7:09 PM EST) -- The majority of members on a U.S. Food and Drug Administration advisory committee has reportedly found that GE Healthcare's Omniscan and Covidien's Optimark — both magnetic resonance imaging drugs — appear to pose a higher risk for a life-threatening skin disease in certain patients than other imaging agents.

Most of the FDA panel said that data indicated that the GE and Covidien drugs included an increased risk of nephrogenic systemic fibrosis in patients with severe kidney impairment, Reuters reported Tuesday.

On Wednesday, an FDA spokesperson said...
To view the full article, register now.